Aerpio Therapeutics is a biopharmaceutical company focused on the development of novel therapeutics for vascular disorders with a concentration on diseases of the eye.
Our lead programs include a Tie-2 activator for diabetic macular edema (DME) and a hypoxia-inducible factor 1-α (HIF1-α) stabilizer for the treatment of inflammatory bowel disease. The lead compound for the Tie-2 program, AKB-9778, recently completed a proof-of-concept, phase 2A study (TIME-2), and the HIF1-α stabilization program is rapidly progressing toward the clinic with first-in-human trials expected to start in early 2016.Learn more...
11/17/15 - Aerpio Therapeutics Reports Positive Clinical Results from the Phase 2a Study of Lead Candidate, AKB-9778, in Diabetic Macular Edema (DME): The TIME-2 TrialRead the press release.
10/9/15 - Aerpio Therapeutics to Present TIME-2 Phase 2a Study of AKB-9778 in Diabetic Macular Edema Data at 2015 American Academy of Ophthalmology Annual Meeting Retina Subspecialty DayRead the press release.
10/7/15 - Aerpio Appoints Steve Pakola, M.D. as Chief Medical OfficerRead the press release.